The heat shock response in pancreatitis that is activated via HSP70 protects acinar cells through multiple simultaneous mechanisms. It inhibits trypsinogen activation and modulates NF-κB signaling to limit acinar cell injury. On the other hand, HSP70 is overexpressed in pancreatic cancer and is hijacked by the cellular machinery to inhibit apoptosis. Inhibition of HSP70 in pancreatic cancer by a novel compound, Minnelide, has shown considerable clinical promise. 
| HEAT SHOCK PROTEINS: CHAPERONES OF CELLS IN DISTRESS
A number of pro-survival pathways have evolved to help cells survive harsh conditions. "Heat shock response" is one such evolutionary conserved pathway. A large number of proteins that play an important role in cellular homeostasis are part of this response. That these ubiquitous polypeptides play an important role in "survival" is clear from that fact that they have been observed in, all the way from, prokaryotes and yeasts to humans. survival. In such situations, heat shock response is activated and the over expression of heat shock proteins then help restore proper protein confirmation and homeostasis. Traditionally, heat shock proteins were believed to help in thermo-tolerance, a process where prior sensitization of thermal stimuli helps cope with subsequent heat exposure. [2] [3] [4] However, subsequent research has demonstrated that in addition to heat stress, HSPs respond to a diverse set of cellular stimuli including protection against cytokine release, hypoxia, ischemia, starvation, ultraviolet exposure, and acidosis. [5] [6] [7] [8] [9] [10] Furthermore, studies suggest that their role may extend beyond their protein chaperone function and that they may have other critical roles including signal transduction. Recently, HSPs have also been associated with antigen presentation and chaperoning immunogenic peptides to Class I and class II major histocompatibility molecules, HSP (sHSPs) are usually tissue specific, are ATP independent and, apart from functioning as chaperones for protein folding, are also strong anti-apoptotic effectors. 18 
| HEAT SHOCK PROTEIN 70 SUPERFAMILY
One of the most conserved and well-studied families of heat shock proteins is HSP70 superfamily. These are ATP dependent chaperones that range in size from 66 to 78 kDa and are encoded by a set of 11 genes in humans. The levels of these proteins are transcriptionally regulated by Heat Shock Factors (HSF) which consists of four members: HSF1, HSF2, HSF3, and HSF4. They possess unique and overlapping functions and have tissue-specific patterns of expression. 19 Of these, HSF-1 is the major transcriptional regulator and is required for transactivation of HSP genes and maintenance of thermotolerance. 20 HSF1, induced during times of stress, binds to the promoter of HSP70 to increase its transcription. The constitutively expressed Hsc70/HSP73 and the highly inducible hsp72/hsp70 are localized to the cytosol and nucleus whereas other members of HSP70
family are found in the mitochondria (mTHSP70) as well as in the endoplasmic reticulum (GRP78/BiP). Increasingly though, the terms "constitutive and inducible" HSPs are becoming obsolete as newer findings suggest that the expression of these proteins may be highly tissue and stimuli specific. 21 Nevertheless, the traditionally described inducible form of HSP70 is sensitive to a wide range of stimuli and its modulation holds promising therapeutic potential. Consequently, our review talks about the emerging role of HSP70 in pathological states starting with a general understanding of HSP70 in human disease and eventually focusing on pancreatitis and pancreatic cancer.
| HSP70 IN ACUTE PANCREATITIS
Acute Pancreatitis is an inflammatory disease of the pancreas culminating in acinar cell injury and death. Under physiologic conditions, digestive enzymes are synthesized, stored, and secreted by the pancreatic acinar cells and their intra-acinar activation is prevented by various protective mechanisms. 22 However, during pancreatitis, the inciting stimuli leads to intra-acinar cell activation of the digestive enzyme zymogens, which in turn are believed to activate the cell death and inflammatory pathways. 23 Research suggest that early on during acute pancreatitis, digestive enzyme zymogens fuse with lysosomes where trypsinogen is activated to trypsin. 24, 25 In parallel but independent to these events, NF-κB dependent proinflammatory pathways are activated which lead to release of inflammatory cytokines from acini and thus amplification of the injury at local and systemic levels. 26 Multiple studies have evaluated the protective role of heat shock proteins in acute pancreatitis. These studies have used various methods, including thermal stress, to overexpress HSP70. Wagner et al found that when acini from rat pancreas were exposed to heat, markedly increased expression of the 72 kda HSP-70 molecule was observed. 27 Interestingly, the authors observed that hyperthermia induced HSP70 overexpression protected against organ damage in cerulean induced pancreatitis model. Similar results were observed even in models where HSP70 was induced via non-thermogenic methods. For example, over-expression of HSP70 by beta-adrenergic stimulation protected mice from cerulean induced pancreatitis. 28 Similarly, administration of sodium arsenite induced overexpression of HSP70 provided protection in cerulean as well as in L-arginine-induced model of acute pancreatitis 29 ( Fig. 1A,B) . These findings overwhelmingly suggest that HSP70 is protective against acinar cell injury in pancreatitis and that this protection is independent of the mode of induction of HSP70. Although, HSP70 was the major protein induced by heat stress as well as pharmacologic manipulation, these interventions induce multiple HSPs and it is possible that the protective effects observed with these interventions are due to events other than overexpression of HSP70. This was investigated by Bhagat et al who showed that HSP70 overexpression is in fact responsible for the observed protective role of heat stress using in vitro culture of pancreatic lobules. 30 In this elegant study, two different approaches, namely selective inhibition of HSP70 overexpression using an antisense | 115 approach and pharmacological inhibition were used to understand the contribution of HSP70 in heat stress induced protection against acute pancreatitis. In the presence of HSP70 anti-sense or the pharmacological inhibitor quercetin, the protection against cerulean induced injury was abrogated. These findings indicated that the protection against ceruleaninduced pancreatitis that follows heat stress is mediated by HSP70. The role of HSP70 in protection imparted by heat stress against pancreatic injury was further evaluated in vivo by Bhagat et al 30 In this study, when antisense oligonucleotide specific to HSP70 was administered prior to heat stress, expression of other stress proteins except HSP70 was observed. The protective effect of pre-induced heat stress on ceruleaninduced pancreatitis in these animals was lost indicating that this protective effect is mediated through overexpressed HSP70. But in the group where sense-oligonucleotide for HSP70 was administered prior to heat stress, HSP70 overexpression was not affected and the protective effect of heat stress to cerulean-induced pancreatitis was maintained. As discussed, intra-acinar trypsinogen and NF-κB activation are critical for the pathogenesis of acute pancreatitis 26 and that colocalization of digestive zymogens and lysosomal enzymes is required for intra-acinar trypsin activation. It appears that one of the mechanisms by which HSP70 protects against acinar cell injury is by interfering with the co-localization of trypsinogen containing zymogen granules and lysosomal enzymes. 29 Further dissection of this process suggests that the initial surge of Ca 2+ influx followed by a sustained increase in Ca 2+ levels is required for co-localization and that chelation of intracellular calcium prevents co-localization. 32 Interestingly, HSP70, at least in nonpancreatic cells, has been shown to attenuate this increase in intracellular Ca
2+
. 33 Besides inhibiting intra-acinar trypsin activation, HSP70
overexpression also decreases NF-κB activation by increasing the levels of its endogenous inhibitor iκBα. In summary, HSP70 protects against pancreatic injury by simultaneously downregulating the two important pathways mediating pancreatic acinar cell injury: Intra acinar activation
of digestive enzymes and the NF-kB pathway.
| HEAT SHOCK PROTEIN 70 IN CHRONIC PANCREATITIS
Contrary to the abundance of literature on acute pancreatitis and heat shock response, relatively little is known about the role of heat shock proteins in chronic pancreatitis. Few studies which have addressed this issue provide conflicting results. Unlike the findings in acute pancreatitis, Lee et al did not find any correlation between HSP70.2 polymorphism and disease severity of alcoholic chronic pancreatitis. 34 Another study however observed that HSP70 levels were increased in patients with chronic pancreatitis compared to healthy controls. 35 Work by Gress et al. has corroborated these results and have demonstrated that HSP70 is over-expressed in pancreatic connective tissues and residual acinar cells from patients with chronic pancreatitis. 36 Results from other chronic fibrotic diseases like pulmonary fibrosis suggest a protective role for HSP70 which is believed to be through inhibition of TGF-β1. 37, 38 Because our understanding of the fibro-inflammatory infiltrate in chronic pancreatitis is only beginning to evolve, future studies will hopefully decipher the role of HSP70 in regulating disease severity and progression in chronic pancreatitis.
| HEAT SHOCK PROTEIN 70 AND PANCREATIC CANCER
Whether pro-survival role of HSP70 is good or bad, is a matter of perspective. While HSP70 has been shown to help in homeostasis and recovery in multiple inflammatory disorders, it has been found to be overexpressed in multiple cancer types and is believed to, by virtue of its pro-survival role, contribute to their aggressive biology. 39 In pancreatic cancer, the inducible form of HSP70 is highly expressed in multiple pancreatic cancer cell lines when compared with normal ductal cells (the commonly believed cell of origin of pancreatic cancer 40 ( Fig. 2A) . Similarly, HSP70 levels are markedly elevated in human pancreatic cancer tissue when compared with normal pancreatic tissue at the tumor margins (Fig. 2B ). While overexpression of HSP70 suggests an important role of this protein in cancer cell survival, the definitive evidence regarding the importance of HSP70 in tumorigenesis comes from studies where the impact of manipulation of HSP70 levels on cancer cells is studied. In pancreatic cancer cells, downregulation of HSP70 by siRNA leads to caspase dependent apoptotic cell death 40 ( Fig. 2C) . Similar results were observed when HSP70 is inhibited by quercetin, a naturally occurring flavonoid which inhibits heat shock response. 40 The mechanism by which HSP70 protects cancer cells from cell death is still evolving. Dysregulation of the apoptotic machinery is a major hallmark in cancer 41 and a number of studies have implicated HSP70 in preventing programmed cell death. 40, 42, 43 Our studies in pancreatic cancer suggest that HSP70 inhibits apoptosis by two independent but simultaneous mechanisms, namely attenuation of cytosolic calcium level and stabilization of the lysosomes. Intracellular calcium levels are tightly regulated and it is widely believed that increased transport of calcium from the endoplasmic reticulum to the mitochondria results in mitochondrial membrane permeabilization and subsequent activation of apoptosis. 44 We have observed that downregulation of HSP70 by either siRNA or by quercetin leads to time dependent increases in cytosolic calcium levels. 45 Interestingly, prevention of this cytosolic calcium increase by using cell permeable calcium chelators leads to protection from cell death suggesting that this increased cytosolic calcium plays a role in cell death caused by HSP70 downregulation. Besides downregulation of cytosolic calcium, studies from our laboratory and others [45] [46] [47] has been shown to inhibit apoptosome formation, an important event which is downstream of mitochondrial release of cytochrome c. 48, 49 Studies have also suggested that HSP70 downregulation leads to the release of cytochrome c, suggesting that HSP70 inhibits the apoptosis pathway upstream of mitochondria as well. 50 In fact, HSP70 has been shown to inhibit translocation of the pro-apoptotic molecule Bax to the mitochondrial membrane and thus prevent mitochondrial membrane permeabilization and cytochrome c release. 51 HSP70 has also been shown to inhibit c Jun N-terminal kinase and thus prevent Bid dependent cytochrome c release from the mitochondria. 52 These findings show the often complementary and redundant pathways through which HSP70 serves to prevent apoptosis in pancreatic cancer cells.
| INHIBITION OF HSP70 IN PANCREATIC CANCER
While the heat shock response is involved at multiple levels in evading apoptosis in cancer cells, it also underscores a vulnerability that could be therapeutically targeted. A small molecule screen conducted to discover HSP70 inhibitors identified triptolide, a natural compound derived from the Chinese herb Tryptergium wilfordii, as an effective inhibitor of Heat shock response. 53 In our initial studies, we observed that triptolide at nano-molar doses inhibited HSP70 levels in multiple pancreatic cell lines and at these doses it led to the activation of apoptotic cell death. 54 Interestingly, while it effectively decreased both transcription as well as protein levels of HSP70 in pancreatic cancer cells, triptolide did not affect HSP70 levels in normal human pancreatic ductal cells, pointing to its selectivity towards a transformed system that had an abnormal overexpression of HSP70.
Furthermore, administration of triptolide in mouse models of aggressive orthotopic pancreatic cancer cells produced dramatic decrease in tumor growth (Fig. 2D) . Although, these findings were promising, triptolide was water insoluble and thus had limited clinical application moving forward. To overcome this, we generated a water conventional therapy with Gemcitabine. 55, 57 In summary, Minnelide is effective across multiple independent and complementary models in decreasing tumor burden, metastasis, and increasing overall survival in pancreatic cancer and these studies set the stage for its phase I trial.
| IS KILLING CANCER CELLS ENOUGH? IMPACT OF MINNELIDE ON TUMOR STROMA
Pancreatic Ductal Adenocarcinoma is characterized by a dense desmoplasia. 58 Apart from the cancer associated fibroblasts that make up the bulk of the tumor mass, it also contains a variety of fibroblasts in a genetic model eventually gave way to a more aggressive form of disease. 62 Therefore, an approach that modulates the stroma, rather than eliminates it completely, may be a better alternative moving forward. For example, depletion of hyaluronan, a glycosaminoglycan that increases interstitial pressure in the tumor ECM, improves vascular patency, drug delivery, and ultimately improves survival. 63, 64 In that vein, Minnelide has been shown to decrease HA synthesis in stroma rich models of PDAC and human xenografts by decreasing the expression of hyaluron synthase enzymes. 57 Additionally, tumor collagen content was reduced secondary to decreased activity of PLOD1-4 (procollagen lysine 5 dioxygenase), an enzyme that is involved in collagen stabilization (Fig. 3B) . Together, Minnelide appears to combine stromal modulation with cancer cell death that may hold the key to designing stroma directed therapy in the future.
| CANCER STEM CELLS, THEIR ROLE IN RECURRENCE AND MINNELIDE
A sub-population of cancer cells has been consistently identified in a number of cancers that share stem-like features. 66 They are analogous to normal stem cells in terms of self-renewal and tumorigenicity. 67 The terminology used can be often contentious with some preferring to call them "tumor initiating cells" due to their ability to from tumors in mice at very low numbers. 68 In pancreatic cancer, a number of markers have been used to identify cells that have heightened tumorigenic capability, are resistant to conventional chemotherapy and are able to lie dormant by evading routine immune surveillance. Chemotherapy in pancreatic cancer is fraught with one significant problem, the acquisition of resistance to an initially susceptible drug.
Drug resistance leads to recurrence and advancing disease in almost all pancreatic cancer patients treated with systemic chemotherapy. 75 
| HOW DOES MINNELIDE REDUCE HSP70 LEVELS?
The mechanism of how exactly Minnelide inhibits HSP70 is still unclear. Triptolide, the biologically active form of Minnelide, is known to decrease global transcription by inhibiting RNA polymerase II at very high doses. 80 These concentrations, however, are shown that triptolide inhibits NF-κB 81, 82 and induces endoplasmic reticulum (ER) stress, 83 ultimately leading to cancer cell death.
These multiple effects could perhaps be explained by triptolide's effect on SP-1, a major transcription regulator. 81 We have shown that inhibition of O-Glycolysation of SP-1 by triptolide prevents its nuclear localization and its subsequent DNA binding. SP-1 besides modulating ER is also an upstream regulator of NF-κB and HSF-1.
HSF-1 in turn is the master heat shock transcription factor which controls the expression of HSP70. Thereby, Minnelide in downregulating HSP70 and its downstream anti-apoptotic drives cancer cells towards cell death.
| CONCLUSION
Through our journey of studying HSP70 we have found that it plays a dual role in pancreatic pathology. In the acute inflammatory This dual, chimeric role of HSP70 in pancreatic pathology, if understood and harnessed well, has broad clinical applicability not only in inflammatory diseases but also in cancer.
ACKNOWLEDGMENT
This study was funded by NIH grants R01-CA170946 and R01-CA124723 (to AKS); Authors also want to acknowledge the intra-mural support from Sylvester Comprehensive Cancer Center.
DISCLOSURES
The University of Minnesota has a patent for Minnelide™ (which has been licensed to Minneamrita Therapeutics LLC, Moline, IL). AS has ownership interests (including patents) and is a consultant/advisory board member for Minneamrita Therapeutics LLC. Dr Sulagna
Banerjee is a consultant for Minneamrita Therapeutics, licensee of the intellectual property (Minnelide) being described in the study. The other authors have nothing to disclose.
